Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Lionsgate Studios Corp Common Shares (LION) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Lionsgate Studios Corp Common Shares — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.87 (market cap $41.25B), while Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 12.5× Lionsgate Studios Corp Common Shares's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.1% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 3 Days and Lionsgate Studios Corp Common Shares for 0 Days on average.
| HLN | LION | |
|---|---|---|
Market Cap | $41.25B | $3.31B |
Volume | 13,519,869 | 2,146,134 |
Sector | Health | Technology |
52-Week High | $11.27 | $16.40 |
52-Week Low | $8.70 | $5.91 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $51.03B | $6.82B |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Haleon (HLN) trades at $9.44, down 0.63% today, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with $11.03B revenue, 14.55% net margin, and consistent earnings beats in recent quarters. Recent business developments include successful shelf space negotiations with major retailers and growth from weight-loss drug side-effect products.
The outlook remains positive with 75% analyst buy ratings and improving cash flow projections for 2026. Key opportunities include market share gains and margin expansion, while risks involve competitive pressures and potential margin compression. The stock presents a balanced risk-reward profile for investors seeking exposure to consumer healthcare.
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →
